xi's moments
Home | Innovation

Sinopharm launches Omicron vaccine trial in Hunan

By Wang Xiaoyu | chinadaily.com.cn | Updated: 2022-05-09 21:06

A vial labelled "Sinopharm COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. [Photo/Agencies]

Chinese company Sinopharm began delivering its Omicron-specific vaccine candidate to fully vaccinated people in a major clinical trial which launched in Hunan province on Monday.

The trial, involving over 4,000 participants, is the world's "largest, earliest and most comprehensive" one to test a vaccine specifically designed to tackle the Omicron variant of COVID-19, the company said in a statement released on Monday.

The upgraded vaccine was developed by a Beijing unit under China National Biotech Group, a subsidiary of Sinopharm.

It received approval to launch human trials in Hong Kong on April 13 and then gained permission for trials on the mainland on April 26.

The company first began administering the vaccine to unvaccinated people in a separate trial rolled out in Hangzhou, Zhejiang province on May 1.

Zhang Yuntao, vice-president of China National Biotech Group, said during an earlier interview it will take at minimum three to four months for researchers to complete trials.

Global Edition
BACK TO THE TOP
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349